Literature DB >> 8417178

Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-infected women.

Y Hénin1, L Mandelbrot, R Henrion, R Pradinaud, J P Coulaud, L Montagnier.   

Abstract

In order to estimate the prevalence of viral excretion in cervicovaginal secretions, we made a cross-sectional study of 55 HIV-infected women. The patient population was diverse, including pregnant and nonpregnant women in different disease stages from three centers. Virus replication was found in the cell-free supernatant from 12 of 55 cervicovaginal samples (21.8%) by coculture on the CD4-positive cell line CEM-C113. In addition, cell-associated virus was detected in five of a subgroup of 22 samples testing negatively on cell-free supernatant. The prevalence of HIV in the cell-free supernatant was not related to disease stage, zidovudine therapy, transmission group, or history of sexually transmitted diseases. Excretion of HIV was significantly higher in our population of pregnant women (eight of 21, 38%) compared with an unmatched group of nonpregnant women (four of 34, 11.8%; p = 0.04). These results provide evidence of cell-free virus shedding as well as the presence of cell-associated virus in the genital secretions of HIV-infected women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417178

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  25 in total

1.  Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women.

Authors:  Andrea Lisco; Massimo Barbierato; Josè R Fiore; Paola Gasperini; Anna Favia; Anna Volpe; Maria Chironna; Giuseppe Pastore; Luigi Chieco-Bianchi; Maria Luisa Calabrò
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

Review 2.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

3.  Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Authors:  L Bélec; C Tévi-Bénissan; T Dupré; A S Mohamed; T Prazuck; J Gilquin; J M Kanga; J Pillot
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

4.  Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats.

Authors:  L L O'Neil; M J Burkhard; E A Hoover
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 5.  Clinical aspects of HIV infection in women.

Authors:  G O Coodley; M K Coodley; A F Thompson
Journal:  J Gen Intern Med       Date:  1995-02       Impact factor: 5.128

6.  Detection of simian immunodeficiency virus Gag-specific CD8(+) T lymphocytes in semen of chronically infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex.

Authors:  H L Jordan; M J Kuroda; J E Schmitz; T Steenbeke; M A Forman; N L Letvin
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 7.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

8.  Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies.

Authors:  Mimi Ghosh; John V Fahey; Zheng Shen; Timothy Lahey; Susan Cu-Uvin; Zhijin Wu; Kenneth Mayer; Peter F Wright; John C Kappes; Christina Ochsenbauer; Charles R Wira
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals.

Authors:  H Zhang; O Bagasra; M Niikura; B J Poiesz; R J Pomerantz
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.